提供支持(VCBeat) May. 10, 2021 -- Willing Medical Science and Technology (Beijing) Co., Ltd. (" Willing Medical") recently has raised RMB 100 million in Series Pre-A funding, led by Biolink Capital, with participation from E-Town Capital, Datai Capital, Rongyu Capital and the existing investor Song Rui Yi Qi.
The funds are earmarked for the following strategic directions:
1. Research and development: continuous optimization and upgrading of the PIseq® metagenomic analysis products for detecting pathogens and the one-stop automated mNGS detection system;
2. Registration and application: to accelerate the registration, testing and clinical trials of the hypersensitivity detection kit based on pathogenic metagenomics for bloodstream infection;
3. Clinical detection network: to build a nationwide network of medical testing laboratories and a top domestic marketing team;
4. Skynet Laboratory: to jointly build the "China Pathogenic Microorganism Skynet Laboratory" with top first-class hospitals at grade 3 to build an intelligent analysis platform of pathogenic microorganisms in China.
Willing Medical is a high-tech enterprise focusing on precision medicine of infection. Prior to the end of 2019, the company has obtained tens of millions of yuan in the angel round from Med-Fine Capital. Based on the two major technology platforms of ultra-broad-spectrum metagenomics and ultra-fast microfluidic chip, Microrock Medical innovates the application of metagenomic next-generation sequencing (mNGS) to pathogen detection, which can complete the detection of 24,000+ pathogenic microorganisms such as bacteria, fungi and viruses at one time.
At present, Willing Medical has launched a series of mNGS-related detection products, including the PIseq®, the first hypersensitive metagenomic testing product for bloodstream infection for whole blood samples, and a one-stop automated detection system for mNGS.
About Biolink Capital
Biolink Capital is an equity investment firm of emerging industries, founded in 2020 by senior industry leaders and investors who have been working in the medical field for many years. The company focuses on fields with great potential and high growth, including in-vitro diagnostic, biological medicine, and high-end medical equipment. Biolink Capital has a deep understanding of the industry, with R&D as the driving force and industry convergence as the strategic direction.
Incorporated in February 2009, Beijing E-Town International Investment & Development Co., Ltd (E-Town Capital) is a Stated-owned investment and financing company with the mission of technological innovation and promoting industrial upgrading in Beijing Economic and Technological Development Area. The company mainly invests in the fields of robotics & smart manufacturing, biotechnology & big health, new energy smart car, and new-generation information technology.
渝公网安备 50011202502165号
